{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:23:55Z","timestamp":1791235435784,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1038\/sj.bjc.6605178","type":"journal-article","created":{"date-parts":[[2009,7,14]],"date-time":"2009-07-14T22:49:48Z","timestamp":1247611788000},"page":"263-268","source":"Crossref","is-referenced-by-count":85,"title":["Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis"],"prefix":"10.1038","volume":"101","author":[{"given":"T","family":"Koreckij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L G","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Y","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R L","family":"Vessella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,7,14]]},"reference":[{"key":"BF6605178_CR1","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1038\/sj.onc.1211016","volume":"27","author":"M Asim","year":"2008","unstructured":"Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H (2008) Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 27: 3596\u20133604, doi: 10.1038\/sj.onc.1211016","journal-title":"Oncogene"},{"key":"BF6605178_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2407-6-15","volume":"6","author":"KD Brubaker","year":"2006","unstructured":"Brubaker KD, Brown LG, Vessella RL, Corey E (2006) Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 6: 15, doi: 10.1186\/1471-2407-6-15","journal-title":"BMC Cancer"},{"key":"BF6605178_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/pros.10233","volume":"56","author":"KD Brubaker","year":"2003","unstructured":"Brubaker KD, Vessella RL, Brown LG, Corey E (2003) Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 56: 13\u201322, doi: 10.1002\/pros.10233","journal-title":"Prostate"},{"key":"BF6605178_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/pros.10091","volume":"52","author":"E Corey","year":"2002","unstructured":"Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL (2002) Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52: 20\u201333, doi: 10.1002\/pros.10091","journal-title":"Prostate"},{"key":"BF6605178_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1091\/mbc.E07-03-0227","volume":"19","author":"O Destaing","year":"2008","unstructured":"Destaing O, Sanjay A, Itzstein C, Horne WC, Toomre D, De Camilli P, Baron R (2008) The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in osteoclasts. Mol Biol Cell 19: 394\u2013404, doi: 10.1091\/mbc.E07-03-0227","journal-title":"Mol Biol Cell"},{"key":"BF6605178_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1464-410X.2008.07539.x","volume":"102","author":"DA Galv\u00e3o","year":"2008","unstructured":"Galv\u00e3o DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R (2008) Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 102: 44\u201347, doi: 10.1111\/j.1464-410X.2008.07539.x","journal-title":"BJU Int"},{"key":"BF6605178_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1158\/0008-5472.CAN-03-2420","volume":"64","author":"M Goldenberg-Furmanov","year":"2004","unstructured":"Goldenberg-Furmanov M, Stein I, Pikarsky E, Rubin H, Kasem S, Wygoda M, Weinstein I, Reuveni H, Ben-Sasson SA (2004) Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 64: 1058\u20131066","journal-title":"Cancer Res"},{"key":"BF6605178_CR8","doi-asserted-by":"publisher","first-page":"8633","DOI":"10.1158\/0008-5472.CAN-06-1410","volume":"66","author":"LY Han","year":"2006","unstructured":"Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf III CA, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK (2006) Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 66: 8633\u20138639, doi: 10.1158\/0008-5472.CAN-06-1410","journal-title":"Cancer Res"},{"key":"BF6605178_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/pros.20744","volume":"68","author":"KM Ignatoski","year":"2008","unstructured":"Ignatoski KM, Escara-Wilke JF, Dai JL, Lui A, Dougall W, Daignault S, Yao Z, Zhang J, Day ML, Sargent EE, Keller ET (2008) RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 68: 820\u2013829, doi: 10.1002\/pros.20744","journal-title":"Prostate"},{"key":"BF6605178_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10585-004-2869-0","volume":"21","author":"JA Kiefer","year":"2004","unstructured":"Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, Corey E (2004) The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 21: 381\u2013387","journal-title":"Clin Exp Metastasis"},{"key":"BF6605178_CR11","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658\u20136661","journal-title":"J Med Chem"},{"key":"BF6605178_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/1534735404270757","volume":"3","author":"MF McCarty","year":"2004","unstructured":"McCarty MF (2004) Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 3: 349\u2013380. Review, doi: 10.1177\/1534735404270757","journal-title":"Integr Cancer Ther"},{"key":"BF6605178_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10165-006-0460-z","volume":"16","author":"T Miyazaki","year":"2006","unstructured":"Miyazaki T, Tanaka S, Sanjay A, Baron R (2006) The role of c-Src kinase in the regulation of osteoclast function. Mod Rheumatol 16: 68\u201374. Review, doi: 10.1007\/s10165-006-0460-z","journal-title":"Mod Rheumatol"},{"key":"BF6605178_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/pros.20752","volume":"68","author":"TM Morgan","year":"2008","unstructured":"Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E (2008) RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 68: 861\u2013871, doi; 10.1002\/pros.20752","journal-title":"Prostate"},{"key":"BF6605178_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1471-2407-7-148","volume":"7","author":"C Morrissey","year":"2007","unstructured":"Morrissey C, Kostenuik PL, Brown LG, Vessella RL, Corey E (2007) Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer 7: 148, doi: 10.1186\/1471-2407-7-148","journal-title":"BMC Cancer"},{"key":"BF6605178_CR16","doi-asserted-by":"publisher","first-page":"9185","DOI":"10.1158\/1535-7163.MCT-06-0446","volume":"65","author":"S Nam","year":"2005","unstructured":"Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65: 9185\u20139189, doi; 10.1158\/1535-7163.MCT-06-0446","journal-title":"Cancer Res"},{"key":"BF6605178_CR17","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1158\/0008-5472.CAN-07-2997","volume":"68","author":"SI Park","year":"2008","unstructured":"Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE (2008) Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68: 3323\u20133333, doi: 10.1158\/0008-5472.CAN-07-2997","journal-title":"Cancer Res"},{"key":"BF6605178_CR18","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513\u20131520","journal-title":"N Engl J Med"},{"key":"BF6605178_CR19","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1359\/jbmr.2003.18.10.1882","volume":"18","author":"J Pfitzenmaier","year":"2003","unstructured":"Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E (2003) Characterization of C4-2 prostate cancer bone metastases and their response to castration. J Bone Miner Res 18: 1882\u20131888","journal-title":"J Bone Miner Res"},{"key":"BF6605178_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.bone.2003.06.004","volume":"34","author":"I Recchia","year":"2004","unstructured":"Recchia I, Rucci N, Funari A, Migliaccio S, Taranta A, Longo M, Kneissel M, Susa M, Fabbro D, Teti A (2004) Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1\/2 pathway. Bone 34: 65\u201379, doi: 10.1016\/j.bone.2003.06.004","journal-title":"Bone"},{"key":"BF6605178_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0046-8177(03)00190-4","volume":"34","author":"MP Roudier","year":"2003","unstructured":"Roudier MP, True LD, Higano CS, Vessella H, Ellis W, Lange P, Vessella RL (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34: 646\u2013653, doi: 10.1016\/S0046-8177(03)00190-4","journal-title":"Hum Pathol"},{"key":"BF6605178_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879\u2013882, doi: 10.1093\/jnci\/djh141","journal-title":"J Natl Cancer Inst"},{"key":"BF6605178_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/0092-8674(91)90499-O","volume":"64","author":"P Soriano","year":"1991","unstructured":"Soriano P, Montgomery C, Geske R, Bradley A (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64: 693\u2013702, doi: 10.1016\/0092-8674(91)90499-O","journal-title":"Cell"},{"key":"BF6605178_CR24","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Th\u00e9odore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502\u20131512","journal-title":"N Engl J Med"},{"key":"BF6605178_CR25","first-page":"2577","volume":"54","author":"GN Thalmann","year":"1994","unstructured":"Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: 2577\u20132581","journal-title":"Cancer Res"},{"key":"BF6605178_CR26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z","volume":"77","author":"TT Wu","year":"1998","unstructured":"Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW (1998) Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID\/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 77: 887\u2013894","journal-title":"Int J Cancer"},{"key":"BF6605178_CR27","doi-asserted-by":"publisher","first-page":"15541","DOI":"10.1073\/pnas.0805354105","volume":"105","author":"A Yano","year":"2008","unstructured":"Yano A, Tsutsumi S, Soga S, Lee M, Trepel J, Osada H, Neckers L (2008) Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci USA 105: 15541\u201315546","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF6605178_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nrc1366","volume":"4","author":"TJ Yeatman","year":"2004","unstructured":"Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4: 470\u2013480. Review, doi: 10.1038\/nrc1366","journal-title":"Nat Rev Cancer"},{"key":"BF6605178_CR29","doi-asserted-by":"publisher","first-page":"8028","DOI":"10.1158\/1078-0432.CCR-04-0621","volume":"10","author":"MV Yezhelyev","year":"2004","unstructured":"Yezhelyev MV, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A, Barge A, Green T, Fennell M, Bruns CJ (2004) Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 10: 8028\u20138036","journal-title":"Clin Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605178","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:40:45Z","timestamp":1684413645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["BF6605178"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605178","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}